Ivorat (Bemiparin Sodium)

Bemiparin Sodium is a low molecular weight heparin used to manage venous thromboembolism.

• Prevention of venous thromboembolism in surgical patients: reduces risk of postoperative deep‑vein thrombosis and pulmonary embolism.
• Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension or recurrence.
• Prevention of thromboembolic events in medically ill patients: lowers incidence of clot formation during acute medical illness or immobilization.

• Bemiparin Sodium enhances the activity of antithrombin III, leading to selective inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). By reducing the generation of thrombin and subsequent fibrin formation, it interrupts the coagulation cascade, thereby preventing the development and propagation of intravascular clots. This anticoagulant effect is achieved without markedly affecting platelet function, allowing for predictable pharmacokinetics and dose‑dependent response.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site reactions: erythema, pain, or induration at the administration site.
• Minor bleeding: bruising, epistaxis, or gum bleeding.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Major hemorrhage: internal bleeding such as gastrointestinal or intracranial hemorrhage.
• Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Elevated liver enzymes: abnormal hepatic function tests.

When prescribing Bemiparin Sodium, clinicians should consider several precautionary measures to minimize risk.

• Renal impairment: adjust use or monitor closely in patients with reduced kidney function.
• Active bleeding: avoid in individuals with ongoing hemorrhage or recent major surgery.
• Concomitant anticoagulants: assess bleeding risk when combined with other anticoagulant or antiplatelet agents.
• History of heparin‑induced thrombocytopenia: contraindicated in patients with prior HIT.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Store at ambient temperature: keep in original container, protect from moisture and light, and do not freeze.

Bemiparin Sodium can interact with other medicines, influencing its anticoagulant effect or bleeding risk.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases bleeding risk.
• Potent antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): synergistic effect on hemorrhage.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance minor bleeding.
• Thrombolytic therapy (e.g., alteplase): additive anticoagulant effect.
• Certain antibiotics (e.g., quinolones) that affect platelet function: monitor for bleeding.
• Herbal supplements (e.g., ginkgo, garlic): potential increase in bleeding tendency.